1h Free Analyst Time
The antiemetic drug market is forecasted to grow by USD 1.72 billion during 2023-2028, accelerating at a CAGR of 6.48% during the forecast period. The report on the antiemetic drug market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population globally, growing prevalence of nausea and vomiting, and increasing healthcare expenditure.
The antiemetic drug market is segmented as below:
By Drug Class
- 5-Hydroxytryptamine 3
- Dopamine antagonist
- Neurokinin-1 (NK 1) receptor antagonist
- Cannabinoid receptor antagonist
- Others
By Application
- Chemotherapy
- Surgery
- Gastroenteritis
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the antiemetic drug market covers the following areas:
- Antiemetic drug market sizing
- Antiemetic drug market forecast
- Antiemetic drug market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global antiemetic drug market: Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Inc., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is integration of digital health solutions in antiemetic drug management."
According to the report, one of the major drivers for this market is the rising geriatric population globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Algen Healthcare Ltd.
- Boehringer Ingelheim International GmbH
- Bristol Laboratories Ltd.
- Cadila Pharmaceuticals Ltd.
- Cipla Inc.
- Eagle Pharmaceuticals Inc.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Helsinn Healthcare SA
- Heron Therapeutics Inc.
- Lupin Ltd.
- Merck and Co. Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- RedHill Biopharma Ltd.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
